MDR1 overexpression is therapeutically actionable with competitive and non-competitive blockers of MDR1 function, both resulting in reduced efflux and in increased intracellular concentrations of the drug, collectively leading to increased chemotherapeutic-induced toxicity of cancer cells [129]. The gene discussed is ABCB1; the disease is cancer.